Off-label usage (of drugs and devices) has long been a hot topic. Companies are forbidden to market off-label uses of their products, and Allergan launched a lawsuit to object to that regulation. Unfortunately, they've dropped that lawsuit, see the excerpt below.
Allergan Drops Suit Challenging FDA’s Off-Label Enforcement
The device industry may have lost its best shot at challenging how the FDA regulates off-label use when Allergan agreed to drop its First Amendment lawsuit seeking the right to tell physicians how to safely use a product off label. The company dropped the suit against the FDA last week as part of a $600 million settlement with the Justice Department over its promotion of Botox for off-label uses. Had Allergan successfully pursued the case, device companies would be able to discuss off-label uses as long as they did so honestly and had safety and efficacy data to support the uses, James Beck, an attorney at Dechert, said.
Devices and Diagnostics Letter
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment